Cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy with adjuvant pembrolizumab for early-stage non-small cell lung cancer in the United States
Pharmacology, Toxicology and Pharmaceutical Science
1
13%
Social Sciences
1
13%
Medicine and Dentistry
1
13%
Unknown
5
63%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 August 2024.
All research outputs
#8,753,124
of 26,646,559 outputs
Outputs from Frontiers in immunology
#10,953
of 33,480 outputs
Outputs of similar age
#128,055
of 369,283 outputs
Outputs of similar age from Frontiers in immunology
#253
of 1,219 outputs
Altmetric has tracked 26,646,559 research outputs across all sources so far. This one has received more attention than most of these and is in the 66th percentile.
So far Altmetric has tracked 33,480 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.7. This one has gotten more attention than average, scoring higher than 66% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 369,283 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 64% of its contemporaries.
We're also able to compare this research output to 1,219 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 78% of its contemporaries.
